177.08 USD
+0.75 (+0.43%)
177.08 USD
0 (0%)
Overall BIIB gets a fundamental rating of 6 out of 10. We evaluated BIIB against 530 industry peers in the Biotechnology industry. BIIB gets an excellent profitability rating and is at the same time showing great financial health properties. BIIB is cheap, but on the other hand it scores bad on growth. With these ratings, BIIB could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
In the past year BIIB had a positive cash flow from operations.
BIIB had positive earnings in each of the past 5 years.
In the past 5 years BIIB always reported a positive cash flow from operatings.
1.2 Ratios
BIIB has a Return On Assets of 5.51%. This is amongst the best in the industry. BIIB outperforms 91.89% of its industry peers.
The Return On Equity of BIIB (8.84%) is better than 92.26% of its industry peers.
The Return On Invested Capital of BIIB (9.70%) is better than 94.53% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
Looking at the Profit Margin, with a value of 15.98%, BIIB belongs to the top of the industry, outperforming 92.45% of the companies in the same industry.
BIIB's Profit Margin has declined in the last couple of years.
BIIB's Operating Margin of 28.50% is amongst the best of the industry. BIIB outperforms 96.60% of its industry peers.
In the last couple of years the Operating Margin of BIIB has declined.
BIIB's Gross Margin of 75.24% is amongst the best of the industry. BIIB outperforms 83.77% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
The number of shares outstanding for BIIB has been reduced compared to 5 years ago.
Compared to 1 year ago, BIIB has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.31 indicates that BIIB is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.31, BIIB is doing good in the industry, outperforming 69.25% of the companies in the same industry.
The Debt to FCF ratio of BIIB is 2.78, which is a good value as it means it would take BIIB, 2.78 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.78, BIIB belongs to the top of the industry, outperforming 93.21% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that BIIB is not too dependend on debt financing.
BIIB has a worse Debt to Equity ratio (0.35) than 69.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.31 |
ROIC/WACC1.17
WACC8.26%
2.3 Liquidity
A Current Ratio of 2.72 indicates that BIIB has no problem at all paying its short term obligations.
With a Current ratio value of 2.72, BIIB is not doing good in the industry: 68.87% of the companies in the same industry are doing better.
BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
BIIB has a worse Quick ratio (2.04) than 73.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.56% yearly.
Based on estimates for the next years, BIIB will show a decrease in Revenue. The Revenue will decrease by -0.63% on average per year.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.58, the valuation of BIIB can be described as very reasonable.
97.74% of the companies in the same industry are more expensive than BIIB, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.92, BIIB is valued rather cheaply.
BIIB is valuated reasonably with a Price/Forward Earnings ratio of 11.46.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaper than 98.11% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.46. BIIB is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.58 | ||
| Fwd PE | 11.46 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaper than 97.92% of the companies in the same industry.
BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIIB is cheaper than 98.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.48 | ||
| EV/EBITDA | 7.77 |
4.3 Compensation for Growth
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
177.08
+0.75 (+0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner Change2.73%
Ins Owners0.14%
Ins Owner Change0.74%
Market Cap25.98B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target183.38 (3.56%)
Short Float %4.63%
Short Ratio3.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)2.19%
PT rev (3m)6.33%
EPS NQ rev (1m)-1%
EPS NQ rev (3m)-54.88%
EPS NY rev (1m)-1.85%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.59%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.58 | ||
| Fwd PE | 11.46 | ||
| P/S | 2.58 | ||
| P/FCF | 11.48 | ||
| P/OCF | 10.59 | ||
| P/B | 1.43 | ||
| P/tB | 10.89 | ||
| EV/EBITDA | 7.77 |
EPS(TTM)16.74
EY9.45%
EPS(NY)15.46
Fwd EY8.73%
FCF(TTM)15.42
FCFY8.71%
OCF(TTM)16.73
OCFY9.45%
SpS68.62
BVpS124.11
TBVpS16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.31 |
F-Score5
WACC8.26%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status for BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for BIIB stock?
The Earnings per Share (EPS) of BIOGEN INC (BIIB) is expected to decline by -7.54% in the next year.